Multiple mitochondrial DNA deletion syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:254807
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Multiple mitochondrial DNA deletion syndrome (also known as mitochondrial DNA depletion/deletion syndrome or progressive external ophthalmoplegia with mitochondrial DNA deletions) is a group of genetic disorders characterized by the accumulation of multiple deletions in mitochondrial DNA (mtDNA) within affected tissues. These deletions impair the function of mitochondria — the energy-producing structures in cells — leading to progressive dysfunction of organs with high energy demands. The condition primarily affects the nervous system, skeletal muscles, and eyes, though the liver, heart, and other organs may also be involved depending on the specific genetic subtype. Key clinical features vary by subtype but commonly include progressive external ophthalmoplegia (weakness of the eye muscles causing drooping eyelids and limited eye movement), proximal muscle weakness, exercise intolerance, sensory or sensorimotor neuropathy, ataxia (impaired coordination), sensorineural hearing loss, and dysphagia. Some forms present with more severe neurological involvement including seizures, cognitive decline, or parkinsonism. The disorder can present from childhood through adulthood, with adult-onset forms being more common in certain subtypes. Multiple mitochondrial DNA deletion syndrome is caused by pathogenic variants in nuclear genes responsible for mitochondrial DNA maintenance, including POLG, TWNK (previously C10orf2), RRM2B, SLC25A4 (ANT1), TYMP, DGUOK, TK2, and others. Inheritance can be autosomal dominant or autosomal recessive depending on the gene involved. There is currently no cure for this condition. Treatment is supportive and symptomatic, focusing on management of ptosis (eyelid surgery), physical therapy for muscle weakness, hearing aids for hearing loss, and monitoring for cardiac or hepatic complications. Coenzyme Q10 supplementation and other mitochondrial cofactors are sometimes used, though evidence for their efficacy remains limited.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Multiple mitochondrial DNA deletion syndrome.

View clinical trials →

No actively recruiting trials found for Multiple mitochondrial DNA deletion syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Multiple mitochondrial DNA deletion syndrome community →

Specialists

1 foundView all specialists →
MM
Michio Hirano, MD
NEW YORK, NY
Specialist
PI on 10 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Multiple mitochondrial DNA deletion syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Multiple mitochondrial DNA deletion syndromeForum →

No community posts yet. Be the first to share your experience with Multiple mitochondrial DNA deletion syndrome.

Start the conversation →

Latest news about Multiple mitochondrial DNA deletion syndrome

No recent news articles for Multiple mitochondrial DNA deletion syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Multiple mitochondrial DNA deletion syndrome

What is Multiple mitochondrial DNA deletion syndrome?

Multiple mitochondrial DNA deletion syndrome (also known as mitochondrial DNA depletion/deletion syndrome or progressive external ophthalmoplegia with mitochondrial DNA deletions) is a group of genetic disorders characterized by the accumulation of multiple deletions in mitochondrial DNA (mtDNA) within affected tissues. These deletions impair the function of mitochondria — the energy-producing structures in cells — leading to progressive dysfunction of organs with high energy demands. The condition primarily affects the nervous system, skeletal muscles, and eyes, though the liver, heart, and o

Which specialists treat Multiple mitochondrial DNA deletion syndrome?

1 specialists and care centers treating Multiple mitochondrial DNA deletion syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.